<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656617</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0835</org_study_id>
    <secondary_id>NCI-2010-01500</secondary_id>
    <nct_id>NCT00656617</nct_id>
  </id_info>
  <brief_title>Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest safe dose of vorinostat that
      can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk
      MDS.

      Once the highest safe dose is found, researchers will then try to learn if this combination
      treatment can help to control AML and high-risk MDS in newly diagnosed patients. The safety
      of this treatment combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Vorinostat is designed to change the gene expression profile of leukemia cells, which may
      cause the cells to die.

      Idarubicin is designed to cause breaks in DNA (the genetic material of cells). This may cause
      cancer cells to die.

      Ara-C is designed to insert itself into DNA of cancer cells and stop the DNA from repairing
      itself.

      This dose combination has not been tested in humans before, at this dose level and schedule.

      Study Drug Administration:

      Induction Therapy:

      If you are found to be eligible to take part in this study, you will begin induction therapy.
      During induction therapy, the dose level of vorinostat may vary based on when you join the
      study and on the side effects seen in other participants. The first group of 3 participants
      will receive the highest dose level of vorinostat. If intolerable side effects are
      experienced, the next group of 3 participants will receive a lower dose of vorinostat. This
      will continue until the highest dose of vorinostat with no intolerable side effects is found.
      The dose levels of the other drugs will not change.

      In the Induction phase, you will receive 1 or 2 induction cycles of therapy on the following
      schedule:

        -  On Days 1-3, you will take vorinostat by mouth 3 times a day.

        -  On Days 4-6, you will receive idarubicin through a needle in your vein over 1 hour.

        -  On Days 4-7, you will receive ara-C by vein as a non-stop infusion.

        -  On Days 4-7, you will receive solumedrol or dexamethasone to help reduce the risk of
           side effects associated with ara-C. The drug will be given by vein over a few seconds.

      Consolidation Therapy:

      If the disease responds during Induction, you may be able to receive up to 5 additional 4-6
      week study cycles. During these Consolidation Cycles, you will take the study drugs on the
      following cycle:

        -  On Days 1-3, you will take vorinostat by mouth 3 times a day.

        -  On Days 4 and 5, you will receive idarubicin through a needle in your vein over 5
           minutes.

        -  On Days 4-6, you will receive ara-C by vein as a non-stop infusion.

        -  On Days 4 and 5, you will also receive either solumedrol or dexamethasone by vein over a
           few seconds.

      Maintenance Therapy:

      If you go into remission, you will begin maintenance therapy. While on maintenance therapy,
      you will take vorinostat by mouth 3 times a day on Days 1-14 of each 28-day study cycle. You
      may have up to 12 Maintenance Cycles.

      Study Visits:

      At least every week during Cycle 1, and then at least once a month during each additional
      cycle, blood (about 1-2 teaspoons) will be drawn for routine tests. You will also have
      routine bone marrow aspirates and biopsies before initiating treatment and approximately on
      Day 21 and Day 28 after initiating therapy.

      Length of Study:

      You may continue to receive the study drugs for up to 18 cycles. You will be taken off study
      early if the disease gets worse or intolerable side effects occur.

      This is an investigational study. Idarubicin is FDA approved for use in combination with
      other approved drugs for the treatment of AML. Vorinostat is FDA approved and commercially
      available for the treatment of some forms of cutaneous lymphoma. Ara-C is FDA approved for
      use in the treatment of leukemia. The use of these drugs together is investigational.

      Up to 105 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) at 7 Months</measure>
    <time_frame>PFS Evaluation at 7 months</time_frame>
    <description>Progression-free survival defined as time from date of randomization to first occurrence of having documented disease progression or death due to any cause, whichever comes first. Progression based on tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST). Participants were followed from baseline to disease progression with PFS evaluation at 7 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant Response</measure>
    <time_frame>Monitoring with each 4 week cycle, up to 18 cycles of treatment</time_frame>
    <description>Number of participants with response assessed according RECIST: Complete Response (CR) defined as normalization of marrow (&lt; 5% blasts) and of peripheral blood counts (neutrophil count &gt; 1.109/L, platelet count &gt; 100 x 109/L). Partial response (PR) defined as for CR in terms of peripheral counts but with reduction of marrow blasts by &gt;50% compared to pretreatment values but above &lt;5%. Complete Response without platelet recovery (CRp) = CR, but platelets &lt;100 x 109/L. Progressive disease (PD) defined as increase of blasts to &gt; 10% after an initial response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>Idarubicin + Ara-C + Vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>12 mg/m^2 IV over 1 hour daily for 3 days (days 4 to 6)</description>
    <arm_group_label>Idarubicin + Ara-C + Vorinostat</arm_group_label>
    <other_name>Idamycin PFS速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)</description>
    <arm_group_label>Idarubicin + Ara-C + Vorinostat</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosine arabinoside</other_name>
    <other_name>Cytosar-U速</other_name>
    <other_name>DepoCyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
    <arm_group_label>Idarubicin + Ara-C + Vorinostat</arm_group_label>
    <other_name>Zolinza速</other_name>
    <other_name>SAHA</other_name>
    <other_name>Suberoylanilide Hydroxamic Acid</other_name>
    <other_name>MSK-390</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of 1) AML (World Health Organization (WHO) classification definition of &gt;/=
             20% blasts), or 2) intermediate-2 or high-risk MDS (defined by the IPSS
             classification2).

          2. Patients aged 15 to 65 years;

          3. For the initial run-in phase of the study, patients with relapsed or refractory
             disease or patients with secondary untreated disease are eligible, however, these
             patients must not have had prior exposure to a histone deacetylase inhibitor, prior
             antecedent hematological disorder or secondary disease with complex cytogenetics.

          4. For the actual phase II portion of the study: patients must be chemona誰ve, i.e., not
             have received any chemotherapy (except hydrea) for AML or MDS. They may have received
             hypomethylating agents for prior MDS and transfusions, hematopoietic growth factors or
             vitamins. Temporary prior measures such as apheresis or hydrea are allowed;

          5. In those patients that have received prior therapy, at least 2 weeks need to have
             elapsed before participating in this study. Treatment may start earlier if deemed in
             the best interest of the patient after discussion with the PI of the study ;

          6. Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 2

          7. Serum biochemical values with the following limits unless considered due to leukemia:
             creatinine &lt;/=2 mg/dl; total bilirubin &lt;/=2 mg/dL, unless increase is due to hemolysis
             or congenital disorder; transaminases (SGPT or SGOT) &lt;/=2.5* upper limit of normal
             (ULN);

          8. Ability to swallow oral medication;

          9. Ability to understand and provide signed informed consent;

         10. Cardiac ejection fraction must be &gt;/=50% (by either multiple gated acquisition scan
             (MUGA) scan or echocardiography).

         11. Diagnosis of 1) AML (WHO classification definition of &gt; 20% blasts), or 2)
             intermediate-2 or high-risk MDS (defined by the International Prognostic Scoring
             System (IPSS) classification) with Flt-3 mutation. Flt-3 extension phase.

         12. Patients aged 15 to 65 years are eligible. Flt-3 extension phase.

         13. Patients with relapsed or refractory disease or patients with secondary untreated
             disease are eligible, however, these patients must not have had prior exposure to a
             histone deacetylase inhibitor. All patients should be Flt-3 positive. Flt-3 extension
             phase.

         14. Patients with newly diagnosed Flt3 positive AML are allowed. Flt-3 extension phase.

         15. In those patients that have received prior therapy, at least 2 weeks need to have
             elapsed before participating in this study. Treatment may start earlier if deemed in
             the best interest of the patient after discussion with the PI of the study. Flt-3
             extension phase.

         16. ECOG performance status &lt;/= 2. Flt-3 extension phase.

         17. Serum biochemical values with the following limits unless considered due to leukemia.
             creatinine &lt;/=2 mg/dl; total bilirubin &lt;/=2 mg/dL, unless increase is due to hemolysis
             or congenital disorder - transaminases (SGPT or SGOT) &lt;/=2.5* ULN. Flt-3 extension
             phase.

         18. Ability to swallow oral medication. Flt-3 extension phase.

         19. Ability to understand and provide signed informed consent. Flt-3 extension phase.

         20. Cardiac ejection fraction must be &gt;/=50% (by either MUGA scan or echocardiography).
             Flt-3 extension phase.

        Exclusion Criteria:

          1. Diagnosis of acute promyelocytic leukemia;

          2. Active, uncontrolled, systemic infection considered opportunistic, life threatening or
             clinical significant at the time of treatment, or any severe concurrent disease, which
             in the opinion of the investigator and after discussion with the principal
             investigator, would make the patient inappropriate for study entry;

          3. Male and female patients who are fertile agree to use an effective barrier method of
             birth control (i.e., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy.
             Female patients need a negative serum or urine pregnancy test within 7 days of study
             enrollment (applies only if patient of childbearing potential. Non childbearing is
             defined as 1 year or more postmenopausal or surgically sterilized);

          4. Symptomatic central nervous system (CNS) involvement;

          5. Patient is unable to take and/or tolerate oral medications on a continuous basis;

          6. Patient has known human immunodeficiency virus (HIV) infection or known HIV-related
             malignancy;

          7. Patient has active hepatitis B or C infection. Active disease is defined as elevated
             liver enzymes and/or clinical symptoms of hepatitis in addition to positive blood test
             for hepatitis surface antigen. In the absence of elevated liver enzymes and/or
             clinical symptoms, the blood test for hepatitis core antigens is not required.

          8. Patient is pregnant or breast-feeding;

          9. Patient has a known allergy or hypersensitivity to any component of vorinostat;

         10. Patient has a history of thrombotic disorders;

         11. History of any psychiatric condition that might impair the patient's ability to
             understand or to comply with the requirements of the study or to provide informed
             consent.

         12. Diagnosis of acute promyelocytic leukemia. Flt-3 extension phase.

         13. Active, uncontrolled, systemic infection considered opportunistic, life threatening or
             clinical significant at the time of treatment, or any severe concurrent disease, which
             in the opinion of the investigator and after discussion with the principal
             investigator, would make the patient inappropriate for study entry. Flt-3 extension
             phase.

         14. Male and female patients who are fertile agree to use an effective barrier method of
             birth control (i.e., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy.
             Female patients need a negative serum or urine pregnancy test within 7 days of study
             enrollment (applies only if patient of childbearing potential. Non childbearing is
             defined as 1 year or more postmenopausal or surgically sterilized). Flt-3 extension
             phase.

         15. Symptomatic CNS involvement. Flt-3 extension phase.

         16. Patient is unable to take and/or tolerate oral medications on a continuous basis.
             Flt-3 extension phase.

         17. Patient has known human immunodeficiency virus (HIV) infection or known HIV-related
             malignancy. Flt-3 extension phase.

         18. Patient has active hepatitis B or C infection. Active disease is defined as elevated
             liver enzymes and/or clinical symptoms of hepatitis in addition to positive blood test
             for hepatitis surface antigen. In the absence of elevated liver enzymes and/or
             clinical symptoms, the blood test for hepatitis core antigens is not required. Flt-3
             extension phase.

         19. Patient is pregnant or breast-feeding. Flt-3 extension phase.

         20. Patient has a known allergy or hypersensitivity to any component of vorinostat. Flt-3
             extension phase.

         21. Patient has a history of thrombotic disorders. Flt-3 extension phase.

         22. History of any psychiatric condition that might impair the patient's ability to
             understand or to comply with the requirements of the study or to provide informed
             consent. Flt-3 extension phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Garcia-Manero, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center's Official Website</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <results_first_submitted>February 26, 2015</results_first_submitted>
  <results_first_submitted_qc>February 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2015</results_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>(AML)</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>(MDS)</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Idarubicin</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>Ara-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 106 participants enrolled, three participants completed the study's first run-in induction portion then another 103 participants were enrolled for the second portion of combined drug induction and maintenance. Four of those 103 enrolled participants were not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Idarubicin + Ara-C + Vorinostat</title>
          <description>Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Run-in Induction Phase</title>
              <participants_list>
                <participants group_id="P1" count="3">Initial run-in: Vorinostat induction dose 500 mg orally three times daily for 3 days.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Induction Phase</title>
              <participants_list>
                <participants group_id="P1" count="103">Induction phase following determination of safe combination Vorinostat with Idarubicin.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance Issues</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Move to different clinical trial</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three participants completed the first run-in portion of the study while 99 of remaining 103 additional participants were evaluable for the second phase of the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Idarubicin + Ara-C + Vorinostat</title>
          <description>Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="19" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) at 7 Months</title>
        <description>Progression-free survival defined as time from date of randomization to first occurrence of having documented disease progression or death due to any cause, whichever comes first. Progression based on tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST). Participants were followed from baseline to disease progression with PFS evaluation at 7 months.</description>
        <time_frame>PFS Evaluation at 7 months</time_frame>
        <population>Four (4) participants did not receive treatment therefore were not evaluable for outcome assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Idarubicin + Ara-C + Vorinostat</title>
            <description>Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) at 7 Months</title>
          <description>Progression-free survival defined as time from date of randomization to first occurrence of having documented disease progression or death due to any cause, whichever comes first. Progression based on tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST). Participants were followed from baseline to disease progression with PFS evaluation at 7 months.</description>
          <population>Four (4) participants did not receive treatment therefore were not evaluable for outcome assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Response</title>
        <description>Number of participants with response assessed according RECIST: Complete Response (CR) defined as normalization of marrow (&lt; 5% blasts) and of peripheral blood counts (neutrophil count &gt; 1.109/L, platelet count &gt; 100 x 109/L). Partial response (PR) defined as for CR in terms of peripheral counts but with reduction of marrow blasts by &gt;50% compared to pretreatment values but above &lt;5%. Complete Response without platelet recovery (CRp) = CR, but platelets &lt;100 x 109/L. Progressive disease (PD) defined as increase of blasts to &gt; 10% after an initial response.</description>
        <time_frame>Monitoring with each 4 week cycle, up to 18 cycles of treatment</time_frame>
        <population>Four (4) participants were not treated therefore not evaluable for the outcome assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Idarubicin + Ara-C + Vorinostat</title>
            <description>Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Response</title>
          <description>Number of participants with response assessed according RECIST: Complete Response (CR) defined as normalization of marrow (&lt; 5% blasts) and of peripheral blood counts (neutrophil count &gt; 1.109/L, platelet count &gt; 100 x 109/L). Partial response (PR) defined as for CR in terms of peripheral counts but with reduction of marrow blasts by &gt;50% compared to pretreatment values but above &lt;5%. Complete Response without platelet recovery (CRp) = CR, but platelets &lt;100 x 109/L. Progressive disease (PD) defined as increase of blasts to &gt; 10% after an initial response.</description>
          <population>Four (4) participants were not treated therefore not evaluable for the outcome assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response without platelet recovery (CRp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event (AE) data collected while participants received study drugs up to 18 cycles (4-6 week cycles). Overall study period: 4/15/08 to 4/15/13. Four of the study's second group were not treated and therefore excluded from AE reporting.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Idarubicin + Ara-C + Vorinostat (Phase 1)</title>
          <description>Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
        </group>
        <group group_id="E2">
          <title>Idarubicin + Ara-C + Vorinostat (Phase 2)</title>
          <description>Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/Laboratory, Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI--Select</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU--Select</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Edema: trunk/genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia-Other (Specify)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia--Select</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cardiac General-Other (Specify)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Scleral necrosis/melt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="81" subjects_affected="71" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia (fever unknown origin without clinical/microbiological documented infection)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="111" subjects_affected="67" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Infection (documented clinical/microbiologically), Grade 3-4 neutrophils</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Opportunistic infection associated with Grade 2 or more Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase) -</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin, Other disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Garcia-Manero, MD/Professor, Leukemia Department</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-745-3428</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

